Patient is 33 weeks, 0 days pregnant (estimated due date 3/16/25) and received nirsevimab monoclonal antibody instead of Abrysvo for passive protection to fetus. MA administering vaccine was confused with the wording on the CDC immunization schedule that stated “Either maternal RSV vaccination with Abrysvo or infant immunization with nirsevimab (RSV monoclonal antibody) is recommended to prevent severe respiratory syncytial virus disease in infants.” It was interpreted that either Abrysvo or nisevimab could be administered to the pregnant patient. At this time no adverse effects noted to the patient or fetus.